FTD.F FIN.DE TUBIZE ACT.NOUV.

Healthcare Biotechnology Frankfurt Exchange
238.80 EUR
Close of Nov 12, 2026
167.20 246.00
Market cap
EUR 10.6B
P/E
108.1x
P/B
5.44x
ROE
4.9%
Dividend yield
0.44%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is FTD.F undervalued?

Graham number

The Graham number of FIN.DE TUBIZE ACT.NOUV. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

FIN.DE TUBIZE ACT.NOUV. fundamental analysis

No fundamental analysis for FIN.DE TUBIZE ACT.NOUV. yet.

FIN.DE TUBIZE ACT.NOUV. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About FIN.DE TUBIZE ACT.NOUV.

Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.

Full company profile